Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, ...

The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 ...

Powerful new weight-loss medications are in the works to treat obesity. Doctors explain why more options are needed and the ...

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...